Rocklatan - (0.005%/0.02% ; Ophthalmic Solution)

Generic Name	Latanoprost and Netarsudil Dimesylate	Innovator	Aerie pharma
Dosage	0.005%/0.02% ; Ophthalmic Solution	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	ROCKLATAN 0.02%/0.005% is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*********	*** / ***	**** **, ****	*******	********* ********	******* *** **** *** *** ****
*********	*** / *********	**** **, ****	*******	****	******* *** **** *** *** ****

Chronology Of Events